Catalyst’s Phase III trial of Firdapse in CMS fails to meet goals

CMS are rare neuromuscular disorders that cause fatigable weakness of skeletal muscles. Credit: Gerd Altmann from Pixabay.



  • Catalyst’s Phase III trial of Firdapse in CMS fails to meet goals